Synonyms: Ogsiveo® | PF-03084014 | PF3084014 | Z-3181
nirogacestat is an approved drug (FDA (2023))
Compound class:
Synthetic organic
Comment: Nirogacestat (PF-3084014) is compound 14f in [2] where it is described as a centrally active γ-secretase inhibitor. It is a reversible, non-competitive, and orally bioactive agent. It was proposed an an anti-tumour agent [1,3,11-12].
PF-3084014 was also reported as an inhibitor of the NOTCH signalling pathway which bolstered its oncology credentials [8,11], since NOTCH inhibition promotes cell cycle arrest and induces apoptosis in tumour cells. |
|
Bioactivity Comments |
In a whole cell assay PF-3084014 inhibits γ-secretase activity with an IC50 of 1.2nM [2], measured as a reduction of Aβ formation. The compound also reduced Aβ in guinea pig brain. |